In Vitro Activity of Fluconazole and Voriconazole Against More Than 10000 Yeast Strains: Results of 5-years Prospective ARTEMIS Disk Study in Russia

Clinical Microbiology and Antimicrobial Chemotherapy. 2008; 10(4):345-354

Journal article

Purpose of the study.

From 2003 till 2008 eight research centers in Russia from Ekaterinburg, Irkutsk, Krasnodar, Novosibirsk, Moscow, St. Petersburg and Smolensk took part in ARTEMIS Disk study, the main purpose of which was the monitoring of epidemiology of candidiasis causative agents and resistance of the clinically significant


A total of 10,652 strains were tested during the period of 5 years. The main sources of clinical material were: genital (36.6%), upper respiratory tract (20.3%), lower respiratory tract (12.0%), lower gastrointestinal tract (10.8%), and urinary tract (7.6%). The predominant species were: C. albicans (76.1%), C. glabrata (5.3%), Candida spp. (3.8%), C. krusei (3.4%) and C. parapsilosis (3.1%). C. albicans shows high in vitro susceptibility both to fluconazole (95.9% of susceptible strains) and voriconazole (96.0% of susceptible strains). The lowest activity of fluconazole noted for C. krusei (9.5% of susceptible strains) and C. glabrata (59.3% of susceptible strains). Voriconazole was highly active against all Candida species with the least activity against C. glabrata (74.2% of susceptible strains). Among fluconazole-resistant strains the highest activity of voriconazole was noted against C. krusei (84.4% of susceptible strains) and C. parapsilosis (78.6% of susceptible strains).


Fluconazole retains activity against all Candida species except C. krusei и C. glabrata. Voriconazole is highly activity against all Candida species, except C. glabrata, but including the majority of fluconazole-resistant strains.

0 Abstract
0 Crossref citations